首页 > 市场调查报告书 > 製药

以基因为基之药物开发

多体学市场规模、份额和成长分析（按产品/服务、类型、平台、应用、最终用户和地区划分）—2025-2032年产业预测

市场调查报告书

商品编码

1877997

多体学市场规模、份额和成长分析（按产品/服务、类型、平台、应用、最终用户和地区划分）—2025-2032年产业预测

Multiomics Market Size, Share, and Growth Analysis, By Products and Services (Products, Services), By Type (Single-cell Multiomics, Bulk Multiomics), By Platform, By Application, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月17日 | 出版商:

SkyQuest | 英文 176 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球多体学市场规模预计在 2024 年达到 31 亿美元，从 2025 年的 36.1 亿美元成长到 2033 年的 121.6 亿美元，在预测期（2026-2033 年）内复合年增长率为 16.4%。

全球多体学市场的发展主要得益于对个人化医疗的日益重视以及基因组学和蛋白质组学研究领域的大量投资。多组体学在药物研发和临床诊断的应用不断扩展，加上定序技术和数据分析的进步，正在改变製药业和研究领域的医疗保健格局。推动多组体学需求的关键因素包括精准医疗的发展趋势以及基因组学研发投入的不断增加，而这一切都发生在慢性病盛行率不断上升的背景下。製药公司正在利用多组体学技术来简化药物研发流程、发现抗药性并识别新的治疗标靶。然而，高昂的研发成本、熟练专家的短缺、数据整合问题以及标准化程度有限等挑战可能会阻碍市场成长。

全球体学市场驱动因素

全球多体学市场的主要驱动因素之一是对个人化医疗日益增长的需求。个人化医疗整合了包括基因组学、蛋白质组学和代谢体学在内的体学数据，旨在为每位患者量身定制治疗方案。随着医疗保健朝着更具针对性的治疗方法和预防性方法发展，分析全面的生物学数据有助于识别疾病路径和患者特异性的治疗反应。此外，定序和数据整合技术的进步以及相关成本的下降，使得多组体学应用在临床环境中更具可行性，从而推动了市场成长和创新。

全球多组体学市场限制因素

全球多组体学市场的主要限制因素之一是多体学技术的复杂性和高成本。整合来自基因组学、蛋白质组学和代谢体学等不同体学的数据需要先进的分析技能、尖端技术和大量资金。这种复杂性可能阻碍小规模研究机构和实验室采用这些技术，从而限制整体市场成长。此外，监管方面的挑战以及对跨多体学平台标准化通讯协定的需求进一步加剧了这一困境，限制了多体学在临床实践和研究中的广泛应用，并阻碍了市场扩张。

全球体学市场趋势

全球多组体学市场正经历向临床应用，特别是精准医疗领域，的重大转变。多体学领域的企业正积极寻求将诊断技术应用于包括肿瘤学、心血管疾病和神经病学在内的各个领域。这种对临床应用的关注将有助于疾病的早期发现，改善个人化治疗，并最终提升患者的治疗效果。随着基于多组体学的诊断工具日益普及，预计将为市场参与企业创造大量机会，增强其竞争优势，并促进推动医疗创新边界的合作。这一趋势凸显了医疗解决方案向数据驱动型解决方案的重大转变。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Thermo Fisher Scientific Inc.（United States）
Illumina, Inc.（United States）
Danaher Corporation（United States）
QIAGEN NV（Germany）
Agilent Technologies, Inc.（United States）
PerkinElmer, Inc.（United States）
Bruker Corporation（United States）
Becton, Dickinson and Company（BD）（United States）
F. Hoffmann-La Roche Ltd.（Switzerland）
10x Genomics, Inc.（United States）
Shimadzu Corporation（Japan）
BGI Genomics（China）
Bio-Rad Laboratories, Inc.（United States）
Mission Bio, Inc.（United States）
Standard BioTools（United States）
NanoString Technologies（United States）
CYTENA GmbH（Germany）
Tempus Labs, Inc.（United States）
DNAnexus, Inc.（United States）
Eurofins Scientific SE（Luxembourg）

结论与建议

简介目录

Product Code: SQMIG35G2367

Global Multiomics Market size was valued at USD 3.1 billion in 2024 and is poised to grow from USD 3.61 billion in 2025 to USD 12.16 billion by 2033, growing at a CAGR of 16.4% during the forecast period (2026-2033).

The global multiomics market is driven by a heightened emphasis on personalized medicine, along with significant investments in genomics and proteomics research. The increasing application of multiomics in drug discovery and clinical diagnostics, coupled with advances in sequencing and data analysis, is reshaping the healthcare landscape across pharmaceutical and research sectors. A pivotal aspect fueling demand for multiomics is the trend towards precision medicine, alongside growing investment in genomic R&D amidst rising chronic disease prevalence. Pharmaceutical companies are harnessing multiomics technologies to enhance drug discovery, elucidate drug resistance, and pinpoint new therapeutic targets. However, challenges such as high research costs, a shortage of skilled professionals, data integration issues, and limited standardization may hinder market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiomics Market Segments Analysis

Global Multiomics Market is segmented by Products and Services, Type, Platform, Application, End User and region. Based on Products and Services, the market is segmented into Products and Services. Based on Type, the market is segmented into Single-cell Multiomics and Bulk Multiomics. Based on Platform, the market is segmented into Genomics, Transcriptomics, Proteomics, Metabolomics and Integrated Omics Platforms. Based on Application, the market is segmented into Diagnostics, Drug Discovery and Development, Personalized Medicine, AgriGenomics and Others. Based on End User, the market is segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Clinical Research Organizations (CROs) and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiomics Market

One key market driver for the global multiomics market is the increasing demand for personalized medicine, which leverages the integration of genomics, proteomics, metabolomics, and other omics data to tailor treatments to individual patients. As healthcare shifts towards more targeted therapies and preventive approaches, the ability to analyze comprehensive biological data helps identify disease pathways and patient-specific responses to treatments. Furthermore, advancements in technology and decreasing costs associated with sequencing and data integration are enhancing the feasibility of multiomics applications in clinical settings, thus driving growth and innovation within the market.

Restraints in the Global Multiomics Market

One significant market restraint for the global multiomics market is the high complexity and cost associated with multiomics technologies. The integration of various omics data, such as genomics, proteomics, and metabolomics, requires advanced analytical skills, sophisticated technologies, and substantial financial resources. This complexity can deter smaller research institutions and laboratories from adopting these technologies, limiting overall market growth. Additionally, regulatory challenges and the need for standardized protocols across multiomics platforms further complicate the landscape, restricting the widespread application of multiomics in clinical practice and research, thereby hindering market expansion.

Market Trends of the Global Multiomics Market

The Global Multiomics market is experiencing a significant shift towards clinical applications, particularly in precision medicine. Companies within the multiomics sector are strategically innovating to leverage their technologies for diagnostics across various domains, including oncology, cardiovascular health, and neurology. This focus on clinical translation is enhancing early disease detection and improving treatment personalization, ultimately driving better patient outcomes. As multiomics-based diagnostic tools gain traction, they are expected to create substantial opportunities for market participants, solidifying their competitive edge and fostering collaborations that push the boundaries of healthcare innovation. The trend underscores a pivotal move towards data-driven healthcare solutions.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Multiomics Market Size by Products and Services & CAGR (2026-2033)

Market Overview
Products
- Instruments
- Consumables
- Software
Services

Global Multiomics Market Size by Type & CAGR (2026-2033)

Market Overview
Single-cell Multiomics
Bulk Multiomics

Global Multiomics Market Size by Platform & CAGR (2026-2033)

Market Overview
Genomics
Transcriptomics
Proteomics
Metabolomics
Integrated Omics Platforms

Global Multiomics Market Size by Application & CAGR (2026-2033)

Market Overview
Diagnostics
Drug Discovery and Development
Personalized Medicine
AgriGenomics
Others

Global Multiomics Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Clinical Research Organizations (CROs)
Others

Global Multiomics Market Size & CAGR (2026-2033)

North America (Products and Services, Type, Platform, Application, End User)
- US
- Canada
Europe (Products and Services, Type, Platform, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Products and Services, Type, Platform, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Products and Services, Type, Platform, Application, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Products and Services, Type, Platform, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bruker Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
10x Genomics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shimadzu Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI Genomics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mission Bio, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Standard BioTools (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NanoString Technologies (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CYTENA GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tempus Labs, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DNAnexus, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific S.E. (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments